<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03276468</url>
  </required_header>
  <id_info>
    <org_study_id>GATA</org_study_id>
    <nct_id>NCT03276468</nct_id>
  </id_info>
  <brief_title>Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas</brief_title>
  <official_title>A Phase II Trial Evaluating Combination of Atezolizumab, With Venetoclax and Obinutuzumab for Relapsed/Refractory Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Lymphoma Academic Research Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Lymphoma Academic Research Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter phase II trial which primary objective is to assess the&#xD;
      anti-lymphoma activity of atezolizumab associated with a BCL-2 inhibitor (GDC-199,&#xD;
      venetoclax) and an anti-CD20 monoclonal antibody (obinutuzumab) in three separate cohorts:&#xD;
&#xD;
        -  relapsed/refractory follicular lymphoma (FL) patients&#xD;
&#xD;
        -  relapsed/refractory aggressive (DLBCL) lymphoma patients&#xD;
&#xD;
        -  relapsed/refractory other indolent (iNHL) lymphoma patients (MZL and MALT)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 12, 2018</start_date>
  <completion_date type="Actual">August 24, 2022</completion_date>
  <primary_completion_date type="Actual">September 19, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This study is a multicentric open-label phase II trial in 3 cohorts of patients</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FL and DLBCL cohorts : Overall Metabolic Response Rate (OMRR) at the end of induction</measure>
    <time_frame>8 months (8 cycles)</time_frame>
    <description>Assessment of disease response according to Lugano 2014</description>
  </primary_outcome>
  <primary_outcome>
    <measure>for iNHL cohort : Overall Response Rate (ORR) at the end of induction</measure>
    <time_frame>8 months (8 cycles)</time_frame>
    <description>Assessment of disease response according to Lugano 2014</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>4 years</time_frame>
    <description>time from inclusion to the first observation of progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>4 years</time_frame>
    <description>time from inclusion to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DR)</measure>
    <time_frame>4 years</time_frame>
    <description>from a confirmed Complete Metabolic Response / Complete Radiologic Response (CMR/CRR) or Partial Metabolic Response / Partial Radiologic Response (PMR/PRR) the first observation of progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>for FL and DLBCL cohorts : OMRR</measure>
    <time_frame>4 months, 18 months</time_frame>
    <description>According to Lugano 2014</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>for iNHL cohort : ORR</measure>
    <time_frame>4 months, 18 months</time_frame>
    <description>According to Lugano 2014</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best response</measure>
    <time_frame>18 months</time_frame>
    <description>Percentage of each response type according to Lugano 2014</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">136</enrollment>
  <condition>Follicular Lymphoma</condition>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <condition>Marginal Zone Lymphoma</condition>
  <condition>Mucosa Associated Lymphoid Tissue</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of venetoclax, atezolizumab and obinutuzumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>1200 mg on day 2 of each 21-day cycle during 18 months (24 cycles)</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Tecentriq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obinutuzumab</intervention_name>
    <description>1000 mg on day 1, day 8 and day 15 of cycle 1 and each day 1 from cycle 2 to cycle 8</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Gazyvaro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>800 mg/d from day 8 of cycle 1, every day during 18 months. For MZL patients wiht lymphocytes&gt;5 g/l : 50 mg/day: week 1 100mg/day: week 2 200mg/day: week 3 400mg/day: week 4 800mg/day: from week 5</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Venclyxto</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically documented CD20-positive follicular lymphoma (WHO grade 1, 2, or 3a)&#xD;
             patients for cohort 1&#xD;
&#xD;
          -  Patients with either histologically documented CD20-positive Diffuse large-cell&#xD;
             lymphoma (including transformations of low-grade lymphoma into DLBCL) or follicular&#xD;
             lymphoma CD20+ grade 3b, or primary cutaneous DLBCL leg type, or primary mediastinal&#xD;
             (thymic) large B-cell lymphoma, or high-grade B-cell lymphoma with MYC and BCL2 and/or&#xD;
             BCL6 rearrangements, or unclassifiable B-cell lymphoma with features intermediate&#xD;
             between DLBCL and Hodgkin (WHO classification) for cohort 2&#xD;
&#xD;
          -  Patients with relapsed/refractory indolent lymphoma (marginal zone (MZL) or measurable&#xD;
             mucosa-associated lymphoid tissue (MALT) lymphoma) for cohort 3&#xD;
&#xD;
          -  Relapsed/refractory NHL after ≥1 prior R-containing regimen with no curative option&#xD;
&#xD;
          -  Aged 18 years or more with no upper age limit&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2&#xD;
&#xD;
          -  Bi-dimensionally measurable disease defined by at least one single node or tumor&#xD;
             lesion &gt; 1.5 cm assessed by CT scan, or Positron Emission Tomography (PET) scan&#xD;
             without IV contrast at diagnosis with at least one hypermetabolic lesion&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  Females of childbearing potential (FCBP) must agree to use one reliable form of&#xD;
             contraception or to practice complete abstinence from heterosexual contact during the&#xD;
             following time periods related to this study: 1) for at least 28 days before starting&#xD;
             study drug; 2) while participating in the study; 3) dose interruptions; and 4) for at&#xD;
             least 18 months after discontinuation of all study treatments&#xD;
&#xD;
          -  Male patients and their partner (FCBP) must agree to use two reliable forms of&#xD;
             contraception (condom for males and hormonal method for partners) during the following&#xD;
             time periods related to this study: 1) for at least 28 days before starting study&#xD;
             drug; 2) while participating in the study; 3) dose interruptions; and 4) for at least&#xD;
             18 months after discontinuation of all study treatments&#xD;
&#xD;
          -  Patient covered by any social security system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lymphocytic lymphoma (LL), waldenström macroglobulinemia, unmeasurable MALT lymphoma,&#xD;
             Mantle Cell Lymphoma (MCL) and Follicular lymphoma for cohort 3&#xD;
&#xD;
          -  Known CD20 negative status at last biopsy done (Biopsy at relapse/progression is&#xD;
             mandatory)&#xD;
&#xD;
          -  Central nervous system or meningeal involvement by lymphoma&#xD;
&#xD;
          -  Prior history of Progressive Multifocal Leukoencephalopathy (PML)&#xD;
&#xD;
          -  Documented infection with HIV&#xD;
&#xD;
          -  Active Hepatitis B (HB) (positive Hepatitis B surface antigen (Ag-HBs) OR positive&#xD;
             serology to hepatitis B (positive Ag-HBs or Hepatitis B core antibody (anti-HBc) or&#xD;
             Polymerisation Chain Reaction (PCR) for viral DNA of HBV) Active Hepatitis C (HC)&#xD;
             infection (patients with positive HCV serology (anti-HCV) are eligible only if PCR is&#xD;
             negative from known HCV RNA)&#xD;
&#xD;
          -  Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection&#xD;
             (excluding fungal infections of nail beds) before inclusion, or any major episode of&#xD;
             infection requiring treatment with IV antibiotics or hospitalization (relating to the&#xD;
             completion of the course of antibiotics) within 4 weeks prior to first administration&#xD;
             of study drug&#xD;
&#xD;
          -  Active immune-related disease criteria&#xD;
&#xD;
          -  Left Ventricular Ejection Fraction (LVEF) &lt; 45% as determined by echocardiography or&#xD;
             multiple uptake gated acquisition (MUGA) scan&#xD;
&#xD;
          -  Any serious active disease or co-morbid medical condition (such as New York Heart&#xD;
             Association Class III or IV cardiac disease, severe arrhythmia, myocardial infarction&#xD;
             within the last 6 months, unstable arrhythmias, or unstable angina) or pulmonary&#xD;
             disease (including uncontrolled obstructive pulmonary disease and history of&#xD;
             bronchospasm or other according to investigator's decision)&#xD;
&#xD;
          -  Clinically significant history of liver disease, including viral or other hepatitis,&#xD;
             current alcohol abuse, or cirrhosis&#xD;
&#xD;
          -  Any of the following laboratory abnormalities:&#xD;
&#xD;
          -  Hemoglobin &lt; 9 g/dL&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &lt; 1,000 cells/mm3 (1.0 G/L) unless due to lymphoma&#xD;
&#xD;
          -  Platelet count &lt; 75,000/mm3 (75 x 109/L) unless due to lymphoma&#xD;
&#xD;
          -  Serum glutamic-oxaloacetic transaminase (SGOT) / Aspartate Transaminase (AST) or Serum&#xD;
             Glutamic-Pyruvate Transferase (SGPT) / Alanine Transaminase (ALT) 3.0 x upper limit of&#xD;
             normal (ULN) unless disease involvement&#xD;
&#xD;
          -  Serum total bilirubin &gt; 2.0 mg/dL (34 μmol/L), except if disease related or in case of&#xD;
             Gilbert syndrome&#xD;
&#xD;
          -  Calculated creatinine clearance (Cockcroft-Gault formula or MDRD) of &lt; 50 mL /min&#xD;
&#xD;
          -  International normalized ratio (INR) ≤ 1.5 x ULN for patients not receiving&#xD;
             therapeutic anticoagulation&#xD;
&#xD;
          -  Partial thromboplastin time (PTT) or activated PTT (aPTT) &gt; 1.5 x ULN&#xD;
&#xD;
          -  Prior history of malignancies other than lymphoma unless the subject has been free of&#xD;
             the disease for ≥ 3 years. Exceptions will be allowed for patients with non-melanoma&#xD;
             skin tumors (basal cell or squamous cell carcinoma of the skin) or any surgically&#xD;
             removed stage 0 (in situ) carcinoma&#xD;
&#xD;
          -  Any serious medical condition, laboratory abnormality (other than mentioned above), or&#xD;
             psychiatric illness that would prevent the subject from signing the informed consent&#xD;
             form&#xD;
&#xD;
          -  Contraindication to any drug contained in the study treatment regimen&#xD;
&#xD;
          -  Previous treatment with obinutuzumab, atezolizumab or venetoclax&#xD;
&#xD;
          -  Use of any standard or experimental anti-cancer drug therapy within 28 days prior to&#xD;
             first administration of study drug&#xD;
&#xD;
          -  Use of warfarin prior to first administration of study drug and throughout all&#xD;
             treatment period (because of potential drug-drug interactions that may potentially&#xD;
             increase the exposure of warfarin)&#xD;
&#xD;
          -  Patients taking corticosteroids within 4 weeks prior to first administration of study&#xD;
             drug, unless administered at a cumulated dose equivalent to ≤ 3.5mg/kg (within these 4&#xD;
             weeks).&#xD;
&#xD;
          -  Use of the following agents prior to first administration of study drug: Strong and&#xD;
             moderate CYP3A inhibitors (including grapefruit juice); Strong and moderate CYP3A&#xD;
             inducers&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Person deprived of his/her liberty by a judicial or administrative decision&#xD;
&#xD;
          -  Adult person under legal protection&#xD;
&#xD;
          -  Person hospitalized without consent&#xD;
&#xD;
          -  Adult person unable to provide informed consent because of intellectual impairment,&#xD;
             any serious medical condition, laboratory abnormality or psychiatric illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillaume CARTRON, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lymphoma Study Association</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles HERBAUX, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lymphoma Study Association</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont Ferrand - Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Annecy Gennevois</name>
      <address>
        <city>Epagny</city>
        <zip>74370</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHD de Vendée</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy - Brabois</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>62000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Lyon Sud</name>
      <address>
        <city>Pierre Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes - Hôpital de Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie - Hôpital René Huguenin</name>
      <address>
        <city>Saint-Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer de Toulouse - Oncopole</name>
      <address>
        <city>Toulouse</city>
        <zip>31100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>September 7, 2017</study_first_submitted>
  <study_first_submitted_qc>September 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 8, 2017</study_first_posted>
  <last_update_submitted>January 9, 2023</last_update_submitted>
  <last_update_submitted_qc>January 9, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>venetoclax; obinutuzumab; atezolizumab; lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
    <mesh_term>Obinutuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03276468
org study id: GATA
nct id: NCT03276468
lead sponsor: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
This study is a multicenter phase II trial which primary objective is to assess the
      anti-lymphoma activity of atezolizumab associated with a BCL-2 inhibitor (GDC-199,
      venetoclax) and an anti-CD20 monoclonal antibody (obinutuzumab) in three separate cohorts:

        -  relapsed/refractory follicular lymphoma (FL) patients

        -  relapsed/refractory aggressive (DLBCL) lymphoma patients

        -  relapsed/refractory other indolent (iNHL) lymphoma patients (MZL and MALT)
allocation: N/A
intervention model: Single Group Assignment
intervention model description: This study is a multicentric open-label phase II trial in 3 cohorts of patients
primary purpose: Treatment
masking: None (Open Label)
measure: FL and DLBCL cohorts : Overall Metabolic Response Rate (OMRR) at the end of induction
time frame: 8 months (8 cycles)
description: Assessment of disease response according to Lugano 2014
measure: for iNHL cohort : Overall Response Rate (ORR) at the end of induction
time frame: 8 months (8 cycles)
description: Assessment of disease response according to Lugano 2014
measure: Progression Free Survival (PFS)
time frame: 4 years
description: time from inclusion to the first observation of progression
measure: Overall Survival (OS)
time frame: 4 years
description: time from inclusion to death
measure: Duration of Response (DR)
time frame: 4 years
description: from a confirmed Complete Metabolic Response / Complete Radiologic Response (CMR/CRR) or Partial Metabolic Response / Partial Radiologic Response (PMR/PRR) the first observation of progression
measure: for FL and DLBCL cohorts : OMRR
time frame: 4 months, 18 months
description: According to Lugano 2014
measure: for iNHL cohort : ORR
time frame: 4 months, 18 months
description: According to Lugano 2014
measure: Best response
time frame: 18 months
description: Percentage of each response type according to Lugano 2014
arm group label: Experimental
arm group type: Experimental
description: Combination of venetoclax, atezolizumab and obinutuzumab
intervention type: Drug
intervention name: Atezolizumab
description: 1200 mg on day 2 of each 21-day cycle during 18 months (24 cycles)
arm group label: Experimental
other name: Tecentriq
intervention type: Drug
intervention name: Obinutuzumab
description: 1000 mg on day 1, day 8 and day 15 of cycle 1 and each day 1 from cycle 2 to cycle 8
arm group label: Experimental
other name: Gazyvaro
intervention type: Drug
intervention name: Venetoclax
description: 800 mg/d from day 8 of cycle 1, every day during 18 months. For MZL patients wiht lymphocytes>5 g/l : 50 mg/day: week 1 100mg/day: week 2 200mg/day: week 3 400mg/day: week 4 800mg/day: from week 5
arm group label: Experimental
other name: Venclyxto
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Guillaume CARTRON, PhD
role: Principal Investigator
affiliation: Lymphoma Study Association
last name: Charles HERBAUX, MD
role: Principal Investigator
affiliation: Lymphoma Study Association
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: France
responsible party type: Sponsor
mesh term: Lymphoma
mesh term: Lymphoma, B-Cell, Marginal Zone
mesh term: Lymphoma, Large B-Cell, Diffuse
mesh term: Atezolizumab
mesh term: Venetoclax
mesh term: Obinutuzumab
sharing ipd: No